Dr. Amar Gajjar, MD
Claim this profileSt. Jude Children's Research Hospital
Studies Brain Tumor
Studies Astrocytoma
10 reported clinical trials
19 drugs studied
Area of expertise
1Brain Tumor
H3.3K27M positive
H3F3A
IDH positive
2Astrocytoma
BRAF negative
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Amar Gajjar, MD is currently running
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
Dabrafenib + Trametinib + Hydroxychloroquine
for Brain Tumor
This phase I/II trial is designed to study the side effects, best dose and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children with low grade or high grade brain tumors previously treated with similar drugs that did not respond completely (progressive) or tumors that came back while receiving a similar agent (recurrent). Patients must also have specific genetic mutations including BRAF V600 mutations or BRAF fusion/duplication, with or without neurofibromatosis type 1. Neurofibromatosis type 1 is an inherited genetic condition that causes tumors to grow on nerve tissue. Hydroxychloroquine, works in different ways to stop the growth of tumor cells by killing the cells or stopping them from dividing. Trametinib and dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine with trametinib and/or dabrafenib may lower the chance of brain tumors growing or spreading compared to usual treatments.
Recruiting1 award Phase 1 & 216 criteria
More about Amar Gajjar, MD
Clinical Trial Related4 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Amar Gajjar, MD has experience with
- Dabrafenib
- Trametinib
- K27M Peptide
- Nivolumab
- INCB7839
- BGB-290
Breakdown of trials Amar Gajjar, MD has run
Brain Tumor
Astrocytoma
Glioblastoma
Diffuse Intrinsic Pontine Glioma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Amar Gajjar, MD specialize in?
Amar Gajjar, MD focuses on Brain Tumor and Astrocytoma. In particular, much of their work with Brain Tumor has involved H3.3K27M positive patients, or patients who are H3F3A.
Is Amar Gajjar, MD currently recruiting for clinical trials?
Yes, Amar Gajjar, MD is currently recruiting for 4 clinical trials in Memphis Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Amar Gajjar, MD has studied deeply?
Yes, Amar Gajjar, MD has studied treatments such as Dabrafenib, Trametinib, K27M peptide.
What is the best way to schedule an appointment with Amar Gajjar, MD?
Apply for one of the trials that Amar Gajjar, MD is conducting.
What is the office address of Amar Gajjar, MD?
The office of Amar Gajjar, MD is located at: St. Jude Children's Research Hospital, Memphis, Tennessee 38105 United States. This is the address for their practice at the St. Jude Children's Research Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.